Cerebral Palsy- Market Insights, Epidemiology and Market Forecast 2028

Report / Search Code: RnM3517313   Publish Date: 11 June, 2019

Price
1-user PDF : $ 5980.0  
1-5 User PDF : $ 12980.0  
Site PDF : $ 12980.0  
Enterprise PDF : $ 12980.0

Description:

Report Summary
"Cerebral Palsy- Market Insights, Epidemiology and Market Forecast 2028" report provides the detailed overview of the disease and in depth understanding of historical and forecasted epidemiology. It highlights the existing treatment patterns, potential upcoming drugs and also identifies best of the market opportunities by providing the current and forecasted market revenue, sales trends, and drug uptake during the study period from 2016-2028.

Market Segment by Countries, covering United States
EU5 (Germany, France, Italy, Spain and the United Kingdom)
Japan
Study Period: 2016-2028

Cerebral Palsy Understanding and Treatment Algorithm
The report provides the in depth analysis of the disease overview by providing details such as disease definition, classification, symptoms, etiology, pathophysiology and diagnostic trends. The comprehensive details about treatment algorithms and treatment guidelines for Cerebral Palsy in the US, Europe, and Japan are also provided in the report.

Cerebral Palsy Epidemiology
This section provide the insights about historical and current patient pool and forecasted trend for 7 major markets. It takes in to account the analysis of numerous studies, survey reports as well as KOL's views which helps to recognize the factors behind the current and forecasted trends, diagnosed and treatable patient pool along with assumptions undertaken.

Cerebral Palsy Product Profiles & Analysis
This part of the Cerebral Palsy report encloses the detailed analysis of marketed drugs and Phase III and late Phase II pipeline drugs. It provides the key cross competition which evaluates the drugs on several parameters including, safety & efficacy results, mechanism of action, route, launch dates and designations. This section also covers the market intelligence and tracking of latest happenings, agreements and collaborations, approvals, patent details and other major breakthroughs.

Cerebral Palsy Market Outlook
The Cerebral Palsy market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. This segment analyses the market trend of each marketed drug and late-stage pipeline drugs. This is done by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data is presented with relevant tables and graphs to give a clear view of the market at first sight.

Cerebral Palsy Market Share by Therapies
This section focusses on the rate of uptake of the potential drugs recently launched or will be launched in the market during the study period from 2016-2028. The analysis covers market uptake by drugs, patient uptake by therapies and sales of each drug. This information also helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It provides the comparison of the drugs on the basis of market share and size. This analysis helps in investigating factors important in market uptake and in making financial as well as regulatory decisions.

Cerebral Palsy Report Insights
Patient Population in Cerebral Palsy
Therapeutic Approaches in Cerebral Palsy
Cerebral Palsy Pipeline Analysis
Cerebral Palsy Market Size and Trends
Cerebral Palsy Market Opportunities
Impact of upcoming Therapies in Cerebral Palsy
Cerebral Palsy Report Key Strengths
10 Year Forecast
7MM Coverage
Epidemiology Segmentation
Drugs Uptake
Highly Analyzed Market
Key Cross Competition
Cerebral Palsy Report Assessment
Current Treatment Practices in Cerebral Palsy
Unmet Needs in Cerebral Palsy
Detailed Cerebral Palsy Pipeline Product Profiles
Market Attractiveness
Market Drivers and Barriers
Key Benefits

This report will help to develop Business Strategies by understanding the trends shaping and driving the Cerebral Palsy market
Organize sales and marketing efforts by identifying the best opportunities for Cerebral Palsy market
To understand the future market competition in the Cerebral Palsy market.

Note: We understand the needs of the rapidly changing market and is helping the client by providing the most up to date Report. It usually takes 4-5 days to deliver this kind of Report. The report coverage will depend on the availability of data.

Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Table of Contents

1 Key Insights

2 Cerebral Palsy Market Overview at a Glance
   • 2.1 Market Share (%) Distribution of Cerebral Palsy in 2018
   • 2.2 Market Share (%) Distribution of Cerebral Palsy in 2028

3 Cerebral Palsy: Disease Background and Overview
   • 3.1 Introduction
   • 3.2 Symptoms
   • 3.3 Etiology
   • 3.4 Risk Factor
   • 3.5 Pathophysiology
   • 3.6 Diagnosis
   • 3.7 Treatment

4 Epidemiology and Patient Population
   • 4.1 Key Findings
   • 4.2 Total Prevalent/Incident Patient Population of Cerebral Palsy in 7MM
   • 4.3 Total Prevalent Patient Population of Cerebral Palsy in 7MM – By Countries

5 Epidemiology of Cerebral Palsy by Countries (2016-2028)
   • 5.1 United States - Epidemiology (2016-2028)
     ■ 5.1.1 Assumptions and Rationale
     ■ 5.1.2 Prevalent/Incident Cases of Cerebral Palsy in the United States
     ■ 5.1.3 Sub-Type Specific cases of Cerebral Palsy in the United States
     ■ 5.1.4 Sex-Specific Cases of Cerebral Palsy in the United States
     ■ 5.1.5 Diagnosed Cases of Cerebral Palsy in the United States
     ■ 5.1.6 Treatable Cases of Cerebral Palsy in the United States
   • 5.2 EU5 Countries
     ■ 5.2.1 Germany
       ▪ 5.2.1.1 Assumptions and Rationale
       ▪ 5.2.1.2 Prevalent/Incident Cases of the of Cerebral Palsy in Germany
       ▪ 5.2.1.3 Sub-Type Specific cases of Cerebral Palsy in the Germany
       ▪ 5.2.1.4 Sex-Specific Cases of the Cerebral Palsy in the Germany
       ▪ 5.2.1.5 Diagnosed Cases of the Cerebral Palsy in the Germany
       ▪ 5.2.1.6 Treatable Cases of the Cerebral Palsy
     ■ 5.2.2 France
       ▪ 5.2.2.1 Assumptions and Rationale
       ▪ 5.2.2.2 Prevalent/Incident Cases of the of Cerebral Palsy in the France
       ▪ 5.2.2.3 Sub-Type Specific cases of Cerebral Palsy in the France
       ▪ 5.2.2.4 Sex-Specific Cases of the Cerebral Palsy in the France
       ▪ 5.2.2.5 Diagnosed Cases of the Cerebral Palsy in the France
       ▪ 5.2.2.6 Treatable Cases of the Cerebral Palsy
     ■ 5.2.3 Italy
       ▪ 5.2.3.1 Assumptions and Rationale
       ▪ 5.2.3.2 Prevalent/Incident Cases of the of Cerebral Palsy in the Italy
       ▪ 5.2.3.3 Sub-Type Specific cases of Cerebral Palsy in the Italy
       ▪ 5.2.3.4 Sex-Specific Cases of the Cerebral Palsy in the Italy
       ▪ 5.2.3.5 Diagnosed Cases of the Cerebral Palsy in the Italy
       ▪ 5.2.3.6 Treatable Cases of the Cerebral Palsy
     ■ 5.2.4 Spain
       ▪ 5.2.4.1 Assumptions and Rationale
       ▪ 5.2.4.2 Prevalent/Incident Cases of the of Cerebral Palsy in the Spain
       ▪ 5.2.4.3 Sub-Type Specific cases of Cerebral Palsy in the Spain
       ▪ 5.2.4.4 Sex-Specific Cases of the Cerebral Palsy in the Spain
       ▪ 5.2.4.5 Diagnosed Cases of the Cerebral Palsy in the Spain
       ▪ 5.2.4.6 Treatable Cases of the Cerebral Palsy
     ■ 5.2.5 United Kingdom
       ▪ 5.2.5.1 Assumptions and Rationale
       ▪ 5.2.5.2 Prevalent/Incident Cases of the of Cerebral Palsy in the United Kingdom
       ▪ 5.2.5.3 Sub-Type Specific cases of Cerebral Palsy in the United Kingdom
       ▪ 5.2.5.4 Sex-Specific Cases of the Cerebral Palsy in the United Kingdom
       ▪ 5.2.5.5 Diagnosed Cases of the Cerebral Palsy in the United Kingdom
       ▪ 5.2.5.6 Treatable Cases of the Cerebral Palsy
   • 5.3 Japan
     ■ 5.3.1 Assumptions and Rationale
     ■ 5.3.2 Prevalent/Incident Cases of the of Cerebral Palsy in the Japan
     ■ 5.3.3 Sub-Type Specific cases of Cerebral Palsy in the Japan
     ■ 5.3.4 Sex-Specific Cases of the Cerebral Palsy in the Japan
     ■ 5.3.5 Diagnosed Cases of the Cerebral Palsy in the Japan
     ■ 5.3.6 Treatable Cases of the Cerebral Palsy

6 Current Treatment & Medical practices
   • 6.1 Treatment Algorithm
   • 6.2 Treatment Guidelines

7 Unmet Needs

8 Marketed Product
   • 8.1 Drug A: Company 1
     ■ 8.1.1 Drug Description
     ■ 8.1.2 Mechanism of Action
8.1.3 Clinical Trials Details
8.1.4 Advantages & Disadvantages
8.1.5 Safety and Efficacy
8.1.6 Product Profile

8.2 Drug B: Company 2
8.2.1 Drug Description
8.2.2 Mechanism of Action
8.2.3 Clinical Trials Details
8.2.4 Advantages & Disadvantages
8.2.5 Safety and Efficacy
8.2.6 Product Profile

8.3 Drug C: Company 3
8.3.1 Drug Description
8.3.2 Mechanism of Action
8.3.3 Clinical Trials Details
8.3.4 Advantages & Disadvantages
8.3.5 Safety and Efficacy
8.3.6 Product Profile

8.4 Drug D: Company 4
8.4.1 Drug Description
8.4.2 Mechanism of Action
8.4.3 Clinical Trials Details
8.4.4 Advantages & Disadvantages
8.4.5 Safety and Efficacy
8.4.6 Product Profile

8.5 Drug E: Company 5
8.5.1 Drug Description
8.5.2 Mechanism of Action
8.5.3 Clinical Trials Details
8.5.4 Advantages & Disadvantages
8.5.5 Safety and Efficacy
8.5.6 Product Profile

8.6 : Company 6
8.6.1 Drug Description
8.6.2 Mechanism of Action
8.6.3 Clinical Trials Details
8.6.4 Advantages & Disadvantages
8.6.5 Safety and Efficacy
8.6.6 Product Profile

8.7 : Company 7
8.7.1 Drug Description
8.7.2 Mechanism of Action
8.7.3 Clinical Trials Details
8.7.4 Advantages & Disadvantages
8.7.5 Safety and Efficacy
8.7.6 Product Profile

8.8 : Company 8
8.8.1 Drug Description
8.8.2 Mechanism of Action
8.8.3 Clinical Trials Details
8.8.4 Advantages & Disadvantages
8.8.5 Safety and Efficacy
8.8.6 Product Profile

9 Emerging Drugs
9.1 Key Cross Competition
9.2 Emerging company

9.2.1 Emerging Drug A: Company 17
9.2.1.1 Other Development Activities
9.2.1.2 Clinical Development
9.2.1.3 Clinical Trials Information
9.2.1.4 Safety and Efficacy
9.2.1.5 Advantages and Disadvantages
9.2.1.6 Product Profile

9.2.2 Emerging Drug B: Company 18
9.2.2.1 Other Development Activities
9.2.2.2 Clinical Development
9.2.2.3 Clinical Trials Information
9.2.2.4 Safety and Efficacy
9.2.2.5 Advantages and Disadvantages
9.2.2.6 Product Profile

9.2.3 Emerging Drug C: Company 19
9.2.3.1 Other Development Activities
9.2.3.2 Clinical Development
9.2.3.3 Clinical Trials Information
9.2.3.4 Safety and Efficacy
9.2.3.5 Advantages and Disadvantages
9.2.3.6 Product Profile

9.2.4 Emerging Drug D: Company 20
9.2.4.1 Other Development Activities
9.2.4.2 Clinical Development
9.2.4.3 Clinical Trials Information
9.2.4.4 Safety and Efficacy
9.2.4.5 Advantages and Disadvantages
9.2.4.6 Product Profile

9.2.5 Emerging Drug E: Company 21
9.2.5.1 Other Development Activities
10 7MM Market Analysis

- 10.1 7MM Market Size of Cerebral Palsy
- 10.2 7MM Percentage Share of Drugs Marketed for Cerebral Palsy
- 10.3 7MM Market Sales of Cerebral Palsy by Products

11 The United States Market Outlook

- 11.1 Market Size of Cerebral Palsy in United States
- 11.2 Percentage Share of Drugs Marketed for Cerebral Palsy in United States
- 11.3 Market Sales of Cerebral Palsy by Products in United States
- 11.4 Analysis of Upcoming Therapies and Impact on the Market

12 EU5 Countries Market Outlook

- 12.1 Market Size of Cerebral Palsy in EU5
- 12.2 Market Size of Cerebral Palsy in Germany
  - 12.2.1 Market Size of Cerebral Palsy in Germany
  - 12.2.2 Percentage Share of Drugs Marketed for Cerebral Palsy in Germany
  - 12.2.3 Market Sales of Cerebral Palsy by Products in Germany
  - 12.2.4 Analysis of Upcoming Therapies and Impact on the Market
- 12.3 Market Size of Cerebral Palsy in France
  - 12.3.1 Market Size of Cerebral Palsy in France
  - 12.3.2 Percentage Share of Drugs Marketed for Cerebral Palsy in France
  - 12.3.3 Market Sales of Cerebral Palsy by Products in France
  - 12.3.4 Analysis of Upcoming Therapies and Impact on the Market
- 12.4 Market Size of Cerebral Palsy in Italy
  - 12.4.1 Market Size of Cerebral Palsy in Italy
  - 12.4.2 Percentage Share of Drugs Marketed for Cerebral Palsy in Italy
  - 12.4.3 Market Sales of Cerebral Palsy by Products in Italy
  - 12.4.4 Analysis of Upcoming Therapies and Impact on the Market
- 12.5 Market Size of Cerebral Palsy in Spain
  - 12.5.1 Market Size of Cerebral Palsy in Spain
  - 12.5.2 Percentage Share of Drugs Marketed for Cerebral Palsy in Spain
  - 12.5.3 Market Sales of Cerebral Palsy by Products in Spain
  - 12.5.4 Analysis of Upcoming Therapies and Impact on the Market
- 12.6 Market Size of Cerebral Palsy in United Kingdom
  - 12.6.1 Market Size of Cerebral Palsy in United Kingdom
  - 12.6.2 Percentage Share of Drugs Marketed for Cerebral Palsy in United Kingdom
  - 12.6.3 Market Sales of Cerebral Palsy by Products in United Kingdom
  - 12.6.4 Analysis of Upcoming Therapies and Impact on the Market

13 The Japan Market Outlook

- 13.1 Market Size of Cerebral Palsy in Japan
- 13.2 Percentage Share of Drugs Marketed for Cerebral Palsy in Japan
- 13.3 Market Sales of Cerebral Palsy by Products in Japan
- 13.4 Analysis of Upcoming Therapies and Impact on the Market

14 Cost Analysis of Cerebral Palsy

15 Generic Competition in Cerebral Palsy Market

16 Market Drivers

17 Market Barriers

18 Report Methodology

- 18.1 Methodology/Research Approach
- 18.2 Data Source
  - 18.2.1 Secondary Sources